{"transactions":[{"id":740041,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:21:00.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001591178-26-000002","document":"form4-06122026_080656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000159117826000002/form4-06122026_080656.xml","form_type":"4"}},{"id":741687,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:43:14.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":20215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":20215,"derivative":{"exercise_price":20,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":20215},"source":{"system":"sec-edgar","filing":"0001193125-26-267747","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526267747/ownership.xml","form_type":"4"}},{"id":1142919,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-19T22:50:18.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":0.4017,"expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-25-013723","document":"form4-05192025_100514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925013723/form4-05192025_100514.xml","form_type":"4"}},{"id":1200126,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-19T00:07:51.000Z","date":"2025-03-14","kind":"purchase","planned":false,"acquired":true,"shares":158000,"price":0.6009,"value":94942.2,"ownership":{"direct":false,"nature":"Grantor and Trustee"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.62, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 158,000 shares held by The Klausner Family Revocable Trust of May 8, 2014, 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust and 245,515 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the \"Delaware Trusts\"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein."}],"balance_after":843365,"source":{"system":"sec-edgar","filing":"0001415889-25-008540","document":"form4-03192025_120347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925008540/form4-03192025_120347.xml","form_type":"4"}},{"id":1477393,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-17T20:15:57.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":2.36,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-24-017176","document":"form4-06172024_080654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588924017176/form4-06172024_080654.xml","form_type":"4"}},{"id":1784769,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-09-08T20:30:40.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On September 6, 2023, to align with benchmarking data, the issuers Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Persons total 2023 grants with the updated policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Persons service as a director ends at such annual meeting due to the Reporting Persons failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":55000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-09-07","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-23-048788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123048788/doc4.xml","form_type":"4"}},{"id":1803711,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T20:23:14.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":58020,"price":2.28,"value":132285.6,"ownership":{"direct":false,"nature":"Grantor"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.275 to $2.285, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust, 245,515 shares held by The Isaac Klausner Delaware Trust, and 245,515 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. Raymond James Trust Services of Delaware is the trustee of each of the trusts."}],"balance_after":930880,"source":{"system":"sec-edgar","filing":"0001209191-23-046267","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123046267/doc4.xml","form_type":"4"}},{"id":1849695,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-20T20:45:09.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected\nor the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person\nproviding continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-038439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123038439/doc4.xml","form_type":"4"}},{"id":2150576,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-27T22:14:26.000Z","date":"2022-09-23","kind":"sale","acquired":false,"shares":11100,"price":6.4001,"value":71041.11,"ownership":{"direct":false,"nature":"Grantor"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of 250,000 shares held by The Ariella Klausner Delaware Trust, 238,900 shares held by The Eli Klausner Delaware Trust, 250,000 shares held by The Isaac Klausner Delaware Trust, and 250,000 shares held by The Olivia Klausner Delaware Trust.  The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein.  Raymond James Trust Services of Delaware is the trustee of each of the trusts."}],"balance_after":988900,"source":{"system":"sec-edgar","filing":"0001209191-22-051379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122051379/doc4.xml","form_type":"4"}},{"id":2236197,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-10T20:08:00.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected\nor the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person\nproviding continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":5.31,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-22-035825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122035825/doc4.xml","form_type":"4"}},{"id":2657489,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-06-23T21:36:41.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":3765842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Lyell Investors, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of Lyell Investors, LLC\n(Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting\nPerson disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3765842},"source":{"system":"sec-edgar","filing":"0001209191-21-042798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919121042798/doc4.xml","form_type":"4"}},{"id":2657488,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-06-23T21:36:41.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":3765842,"ownership":{"direct":false,"nature":"Lyell Investors, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of Lyell Investors, LLC\n(Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting\nPerson disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein"}],"balance_after":3765842,"source":{"system":"sec-edgar","filing":"0001209191-21-042798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919121042798/doc4.xml","form_type":"4"}},{"id":4007534,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T18:21:50.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":63.71,"value":764520.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":23.29,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-017815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118017815/doc4.xml","form_type":"4"}},{"id":4007533,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T18:21:50.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":44.6,"value":535200.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":42.4,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-017815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118017815/doc4.xml","form_type":"4"}},{"id":4007532,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T18:21:50.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":27,"value":324000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":60,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-017815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118017815/doc4.xml","form_type":"4"}},{"id":4007531,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-07T18:21:50.000Z","date":"2018-03-05","kind":"other","acquired":false,"shares":705525,"price":87,"value":61380675.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"date","element":"transactionDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118017815/doc4.xml","form_type":"4"}},{"id":4007530,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-07T18:21:50.000Z","date":"2018-02-07","kind":"gift","acquired":false,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a bona fide gift of common stock; thus, there is no price associated with this transaction."}],"balance_after":705525,"source":{"system":"sec-edgar","filing":"0001209191-18-017815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118017815/doc4.xml","form_type":"4"}},{"id":4102710,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-09T21:05:09.000Z","date":"2018-01-08","kind":"sale","acquired":false,"shares":918,"price":49.3696,"value":45321.2928,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $49.34 to $49.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":728775,"source":{"system":"sec-edgar","filing":"0001209191-18-003055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118003055/doc4.xml","form_type":"4"}},{"id":4102709,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-09T21:05:09.000Z","date":"2018-01-08","kind":"sale","acquired":false,"shares":4846,"price":48.9523,"value":237222.8458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $48.34 to $49.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":729693,"source":{"system":"sec-edgar","filing":"0001209191-18-003055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118003055/doc4.xml","form_type":"4"}},{"id":4102708,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-09T21:05:09.000Z","date":"2018-01-08","kind":"sale","acquired":false,"shares":5011,"price":47.8024,"value":239537.8264,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $47.29 to $48.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":734539,"source":{"system":"sec-edgar","filing":"0001209191-18-003055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118003055/doc4.xml","form_type":"4"}},{"id":4102707,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-09T21:05:09.000Z","date":"2018-01-08","kind":"sale","acquired":false,"shares":1949,"price":46.8495,"value":91309.6755,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $46.29 to $47.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":739550,"source":{"system":"sec-edgar","filing":"0001209191-18-003055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118003055/doc4.xml","form_type":"4"}},{"id":4102706,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-09T21:05:09.000Z","date":"2018-01-05","kind":"grant","acquired":true,"shares":248,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":741499,"source":{"system":"sec-edgar","filing":"0001209191-18-003055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919118003055/doc4.xml","form_type":"4"}},{"id":4122192,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-22T16:58:54.000Z","date":"2017-12-21","kind":"sale","acquired":false,"shares":3141,"price":45.1605,"value":141849.1305,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $45.12 to $45.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":741251,"source":{"system":"sec-edgar","filing":"0001209191-17-067084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117067084/doc4.xml","form_type":"4"}},{"id":4122191,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-22T16:58:54.000Z","date":"2017-12-21","kind":"sale","acquired":false,"shares":32859,"price":44.7216,"value":1469507.0544,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $44.12 to $45.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":744392,"source":{"system":"sec-edgar","filing":"0001209191-17-067084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117067084/doc4.xml","form_type":"4"}},{"id":4190074,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-06T19:31:43.000Z","date":"2017-10-05","kind":"grant","acquired":true,"shares":266,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":777251,"source":{"system":"sec-edgar","filing":"0001209191-17-056351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117056351/doc4.xml","form_type":"4"}},{"id":4213349,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-08T19:29:48.000Z","date":"2017-09-07","kind":"sale","acquired":false,"shares":1337,"price":43.833,"value":58604.721,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $43.61 to $44.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":776985,"source":{"system":"sec-edgar","filing":"0001209191-17-052159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117052159/doc4.xml","form_type":"4"}},{"id":4213348,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-08T19:29:48.000Z","date":"2017-09-07","kind":"sale","acquired":false,"shares":5214,"price":42.7579,"value":222939.6906,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $42.48 to $43.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":778322,"source":{"system":"sec-edgar","filing":"0001209191-17-052159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117052159/doc4.xml","form_type":"4"}},{"id":4213347,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-08T19:29:48.000Z","date":"2017-09-07","kind":"sale","acquired":false,"shares":5449,"price":42.2685,"value":230321.0565,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $41.48 to $42.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":783536,"source":{"system":"sec-edgar","filing":"0001209191-17-052159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117052159/doc4.xml","form_type":"4"}},{"id":4238585,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-09T19:43:02.000Z","date":"2017-08-07","kind":"sale","acquired":false,"shares":12000,"price":30.3409,"value":364090.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $30.04 to $30.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":788985,"source":{"system":"sec-edgar","filing":"0001209191-17-048356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117048356/doc4.xml","form_type":"4"}},{"id":4260662,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T19:49:40.000Z","date":"2017-07-07","kind":"sale","acquired":false,"shares":400,"price":29.9975,"value":11999.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $29.97 to $30.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":800985,"source":{"system":"sec-edgar","filing":"0001209191-17-044461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117044461/doc4.xml","form_type":"4"}},{"id":4260661,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T19:49:40.000Z","date":"2017-07-07","kind":"sale","acquired":false,"shares":23600,"price":29.378,"value":693320.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.97 to $29.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":801385,"source":{"system":"sec-edgar","filing":"0001209191-17-044461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117044461/doc4.xml","form_type":"4"}},{"id":4260660,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T19:49:40.000Z","date":"2017-07-05","kind":"grant","acquired":true,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":824985,"source":{"system":"sec-edgar","filing":"0001209191-17-044461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117044461/doc4.xml","form_type":"4"}},{"id":4277002,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-19T16:36:56.000Z","date":"2017-06-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option become vested and exercisable on the earlier of (i) the date of the 2018 Annual Meeting of Stockholders and (ii) the first anniversary of the grant date, in either event, subject to the director continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through such date."}],"balance_after":12000,"derivative":{"exercise_price":23.29,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-040847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117040847/doc4.xml","form_type":"4"}},{"id":4286689,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-09T19:37:21.000Z","date":"2017-06-07","kind":"sale","acquired":false,"shares":8768,"price":24.2391,"value":212528.4288,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $23.73 to $24.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":824605,"source":{"system":"sec-edgar","filing":"0001209191-17-039017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117039017/doc4.xml","form_type":"4"}},{"id":4286688,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-09T19:37:21.000Z","date":"2017-06-07","kind":"sale","acquired":false,"shares":15232,"price":23.2296,"value":353833.2672,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.73 to $23.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":833373,"source":{"system":"sec-edgar","filing":"0001209191-17-039017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117039017/doc4.xml","form_type":"4"}},{"id":4356623,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-06T16:50:09.000Z","date":"2017-04-05","kind":"grant","acquired":true,"shares":514,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":848605,"source":{"system":"sec-edgar","filing":"0001209191-17-026105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117026105/doc4.xml","form_type":"4"}},{"id":4494929,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-09T17:06:31.000Z","date":"2017-01-05","kind":"grant","acquired":true,"shares":591,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":848091,"source":{"system":"sec-edgar","filing":"0001209191-17-002965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919117002965/doc4.xml","form_type":"4"}},{"id":4578867,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":38774,"kind":"person","name":"Klausner Richard","position":1,"cik":"0001591178","reported_name":"Klausner Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-17T20:44:31.000Z","date":"2016-10-05","kind":"grant","acquired":true,"shares":401,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":847500,"source":{"system":"sec-edgar","filing":"0001209191-16-146110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1591178/000120919116146110/doc4.xml","form_type":"4"}}]}